ReviewWorld journal of cardiology2022

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.

Awadhesh Kumar Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.